Biogen

Biogen Inc. is a pioneering biotechnology company founded in 1978 by a distinguished group of Nobel Prize-winning scientists including Walter Gilbert and Phillip Allen Sharp. Headquartered in Cambridge, Massachusetts, Biogen has established itself as a global leader in neuroscience, developing transformative therapies for some of the most challenging neurological and neurodegenerative diseases affecting millions worldwide.

With approximately 7,600 employees and fiscal 2024 revenue of $9.7 billion, Biogen operates at the forefront of biotechnology innovation. The company's primary therapeutic focus areas include neurology (particularly multiple sclerosis), Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and rare diseases. Biogen's marketed products represent breakthroughs in their respective categories, including LEQEMBI for Alzheimer's disease, SPINRAZA for SMA, and a comprehensive multiple sclerosis portfolio featuring TECFIDERA, TYSABRI, VUMERITY, AVONEX, and PLEGRIDY.

The company's journey has been marked by scientific excellence and strategic evolution. Following the 2003 merger with IDEC Pharmaceuticals, Biogen Idec became a powerhouse in biotechnology before reverting to simply Biogen as it refined its strategic focus. Under CEO Christopher Viehbacher's leadership since November 2022, Biogen has undergone significant transformation, streamlining operations, refreshing its board, and adopting a more pragmatic approach to drug development while maintaining its commitment to groundbreaking neuroscience research.

Biogen's research and development pipeline reflects a balanced portfolio approach, combining established revenue-generating products with innovative candidates in various stages of clinical development. The company has made strategic acquisitions to strengthen its position, including the $7.3 billion acquisition of Reata Pharmaceuticals in 2023 (bringing SKYCLARYS for Friedreich's ataxia), the $1.15 billion acquisition of Human Immunology Biosciences in 2024, and the $85 million acquisition of Alcyone Therapeutics in 2025 to enhance drug delivery capabilities.

Despite facing headwinds in its legacy multiple sclerosis franchise, where revenue declined 7% in 2024 due to increased competition, Biogen is successfully launching new products and expanding into immunology and rare disease areas. The company's commitment to scientific innovation, combined with operational discipline and strategic focus, positions Biogen to continue pioneering treatments that transform patients' lives while creating value for shareholders and communities worldwide.